Table 1

The clinico pathologic characteristics of previously reported cases of pyloric gland adenoma [2-15] and the case reported here
Author (year) Number of cases Age/Sex Site Associated lesion Malignancy developing in PGA Size (cm) Immunoreactivity Genetics
Kushima (1996) 1 61/F Gallbladder Gastric metaplasia 1.5 MUC6 (= M2) n.k.
Bakotic (1999) 1 69/F Pancreas (main duct) Heterotopic gastric corpus mucosa 0.9 PAS, negative: Alcian blue, chromogranin, serotonin, somatostatin, gastrin KRAS exon 1 (p.G12R; c.34G>C)
Kushima (1999) 1 67/F Duodenum Heterotopic gastric corpus mucosa 2.5 MUC5AC (= M1), MUC6 (= M2) n.k.
Kato (2002) 1 70/M Pancreas (main duct) IPMN 0.6 PCS, HIK1083, negative: neuroendocrine markers, hormones KRAS exon 1, codon 12
Amaris (2002) 1 73/M Pancreas (branch duct) IPMN n.k. PAS, negative: Alcian blue n.k.
Vieth (2003) 90 73/F:M = 3:1 Stomach (n =77 ), duodenal bulb (n = 7), duodenum (n = 1), common bile duct (n = 3), gallbladder (n = 2) Gastritis (A-, B-, and C-type) (20-34%), tubular adenoma (n = 1), carcinoid tumour (n = 1), adenocarcinoma (n = 1) Adenocarcinoma (30%) 1.6 n.k. n.k.
Vieth (2005) 1 46/M Rectum Heterotopic gastric corpus mucosa 3 MUC6, MUC5AC n.k.
Kushima (2005) 1 62/M Esophagus Barrett's mucosa 3 MUC6, MUC5AC, negative: MUC2, CD10 CGH: losses at 2p24p25.2, 2q14.1pter, 5q31.3q32, 6q23q24, 8q23q24.2,11q22.3q24, 18q21.1q22
Chen (2009) 41 tumours, 36 patients 73/F:M = 25:11 Stomach (19), duodenum (19), gastroesophageal junction (2), pancreas (1) Gastritis (A-type) (40%), intestinal metaplasia (60%) Adenocarcinoma (12.2%) n.k. MUC6, MUC5AC, negative: CDX2, MUC2 n.k.
Wani (2008) 29 n.k. Gallbladder Intestinal metaplasia (34.4%), squamous morules (24.1%) 0.82 MUC6, MUC5AC, M-GGMC-1, morules: CDX2, beta-catenin n.k.
Golger (2008) 1 79/F Stomach Helicobacter-negative gastritis 2 n.k. n.k.
Oh (2010) 1 n.k. Stomach Adenocarcinoma 3.5 MUC6 n.k.
Vieth (2010) 60 70-71/F=M Stomach Adenocarcinoma (46.7%) 0.9-1.5 MUC6, MUC5AC (MUC2, CD10), p53 and Ki67 in malignant transition n.k.
Gutierrez-Grobe (2010) 1 49/F Stomach n.k. MUC6, MUC5AC, negative: MUC2 n.k.
Present case 1 62/M Cystic duct IPN, BilIN-3 Adenocarcinoma 2 MUC5AC, MUC6, VEGF, p53, p21, Ki67, (MUC1, p16), negative: MUC2, CD10, CDX2 KRAS exon 1 (p.G12V; c.35G>T); CGH: gains at 1q, 6p11p22, 7p, 15q, 20p, and losses at 6p23pter, 6q14qter, 11q12q13, 18

PGA: Pyloric gland adenoma.

PAS: Periodic Schiff's acid.

PCS: paradoxical concanavalin A.

IPMN: intraductal papillary mucinous neoplasm.

IPN: intraductal papillary neoplasm.

BilIN: biliary intraepithelial neoplasia.

CGH: comparative genomic hybridization.

Schaefer et al.

Schaefer et al. BMC Cancer 2012 12:570   doi:10.1186/1471-2407-12-570

Open Data